

CLAIMS

1. An isolated polynucleotide being selected from the group consisting of:
- 5 a. a polynucleotide encoding a BMP-2 inducible kinase polypeptide comprising an amino acid sequence selected from the group consisting of:
- 10 i. amino acid sequences which are at least about 72% identical to the amino acid sequence shown in SEQ ID NO: 2; and
- ii. the amino acid sequence shown in SEQ ID NO: 2.
- iii. amino acid sequences which are at least about 72% identical to the amino acid sequence shown in SEQ ID NO: 4; and
- 15 iv. the amino acid sequence shown in SEQ ID NO: 4.
- b. a polynucleotide comprising the sequence of SEQ ID NOS: 1 or 3;
- c. a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a BMP-2 inducible
- 20 kinase polypeptide;
- d. a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a BMP-2 inducible kinase polypeptide;
- 25 and
- e. a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a BMP-2 inducible kinase polypeptide.
- 30
2. An expression vector containing any polynucleotide of claim 1.

- 98 -

3. A host cell containing the expression vector of claim 2.
4. A substantially purified BMP-2 inducible kinase polypeptide encoded by a polynucleotide of claim 1.
5. A method for producing a BMP-2 inducible kinase polypeptide, wherein the method comprises the following steps:
 - 10 a. culturing the host cell of claim 3 under conditions suitable for the expression of the BMP-2 inducible kinase polypeptide; and
 - b. recovering the BMP-2 inducible kinase polypeptide from the host cell culture.
- 15 6. A method for detection of a polynucleotide encoding a BMP-2 inducible kinase polypeptide in a biological sample comprising the following steps:
 - 20 a. hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
 - b. detecting said hybridization complex.
7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.
- 25 8. A method for the detection of a polynucleotide of claim 1 or a BMP-2 inducible kinase polypeptide of claim 4 comprising the steps of:

BEST AVAILABLE COPY

- 99 -

- a. contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the BMP-2 inducible kinase polypeptide and
 - b. detecting the interaction
9. A diagnostic kit for conducting the method of any one of claims 6 to 8.
10. A method of screening for agents which decrease the activity of a BMP-2 inducible kinase, comprising the steps of:
- a. contacting a test compound with any BMP-2 inducible kinase polypeptide encoded by any polynucleotide of claim 1;
 - b. detecting binding of the test compound to the BMP-2 inducible kinase polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a BMP-2 inducible kinase.
11. A method of screening for agents which regulate the activity of a BMP-2 inducible kinase, comprising the steps of:
- a. contacting a test compound with a BMP-2 inducible kinase polypeptide encoded by any polynucleotide of claim 1; and
 - b. detecting a BMP-2 inducible kinase activity of the polypeptide, wherein a test compound which increases the BMP-2 inducible kinase activity is identified as a potential therapeutic agent for increasing the activity of the BMP-2 inducible kinase, and wherein a test compound which decreases the BMP-2 inducible kinase activity of the poly-

BEST AVAILABLE COPY

- 100 -

peptide is identified as a potential therapeutic agent for decreasing the activity of the BMP-2 inducible kinase.

12. A method of screening for agents which decrease the activity of a BMP-2 inducible kinase, comprising the step of:

contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of BMP-2 inducible kinase.

13. A method of reducing the activity of BMP-2 inducible kinase, comprising the step of:

contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any BMP-2 inducible kinase polypeptide of claim 4, whereby the activity of BMP-2 inducible kinase is reduced.

14. A reagent that modulates the activity of a BMP-2 inducible kinase polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.

15. A pharmaceutical composition, comprising:

the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.

16. Use of the expression vector of claim 2 or the reagent of claim 14 in the preparation of a medicament for modulating the activity of a BMP-2 inducible kinase in a disease.

BEST AVAILABLE COPY

- 101 -

17. Use of claim 16 wherein the disease is cancer, diabetes, a CNS disorder, COPD, a gastrointestinal disorder or a cardiovascular disorder.

BEST AVAILABLE COPY